Torin 1

Name: Torin 1
Brand: Selleck Chemicals
SKU: S2827
Rating: 5 (119 reviews)

For research use only.

Catalog No.S2827

119 publications

CAS No. 1222998-36-8

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Selleck's Torin 1 has been cited by 119 publications

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Nat Biotechnol, 2020, 38(5):638-648

PubMed: 32249828 ( click the link to review the publication )

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Nature, 2017, 1;546(7656):168-172.

PubMed: 28538732 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(10):1170-1179

PubMed: 32989246 ( click the link to review the publication )

Sci Transl Med, 2020, 12(548):eaay5691

PubMed: 32554707 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):479

PubMed: 31980602 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Cell Rep, 2020, 30(5):1400-1416

PubMed: 32023458 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1835-1847

PubMed: 32049014 ( click the link to review the publication )

PLoS Pathog, 2020, 9;16(6):e1008568

PubMed: 32516328 ( click the link to review the publication )

Cell Death Dis, 2020, 8;5:e1214

PubMed: 24810050 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439931 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

J Immunol, 2020, ji2000244

PubMed: 32989095 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786

PubMed: 32169890 ( click the link to review the publication )

Int J Mol Sci, 2020, 24;21(6) pii: E2240

PubMed: 32213867 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

J Clin Invest, 2020, 137585

PubMed: 32673292 ( click the link to review the publication )

Emerg Microbes Infect, 2020, 9(1):1748-1760

PubMed: 32691695 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.13703

PubMed: 32683324 ( click the link to review the publication )
bioRxiv, 2020, 2020.10.09.334128

PubMed: 33052348 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1364147

PubMed: 32724488 ( click the link to review the publication )

Nat Metab, 2020, 2(1):41-49

PubMed: 31993556 ( click the link to review the publication )

Cancer Res, 2020, 80(3):444-457

PubMed: 31722999 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )
Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )
Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(5):5521-37

PubMed: 26575168 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )
Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NXHXPFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\3SWlEPTB;MD6wNFA{ODZizszN	M{HBTXNCVkeHUh?=
OCUB-M	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlG5TWM2OD1yLkCwNVk1KM7:TR?=	M{PaWnNCVkeHUh?=
DOHH-2	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3YTWM2OD1yLkCwNlI2KM7:TR?=	NIfp[XFUSU6JRWK=
NOS-1	M1K5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDheW52UUN3ME2wMlAxOjR{IN88US=>	NFHDOFdUSU6JRWK=
L-363	NVP1WXVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXETWM2OD1yLkCwNlg1KM7:TR?=	MnPTV2FPT0WU
RL95-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrFfZFEUUN3ME2wMlAxOzJizszN	NIfpN\|FUSU6JRWK=
BL-70	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEm3OFBKSzVyPUCuNFA{OzdizszN	Mn;FV2FPT0WU
TGBC1TKB	M1TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2xWXhKSzVyPUCuNFA{PzlizszN	Mo\vV2FPT0WU
697	NHzDfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D2VmlEPTB;MD6wNFY{PCEQvF2=	MnjLV2FPT0WU
RPMI-8226	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEC2OVEh\|ryP	NUHlTnlRW0GQR1XS
BL-41	MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMEC2PVYh\|ryP	NW\keXI4W0GQR1XS
MRK-nu-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPNb5k{UUN3ME2wMlAxPzB5IN88US=>	NHvGN3pUSU6JRWK=
EW-1	NYDoNIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf4TWM2OD1yLkCwO\|Q6KM7:TR?=	MWDTRW5ITVJ?
EVSA-T	M4KwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[1b3Q1UUN3ME2wMlAxQDl{IN88US=>	NVLQeFZrW0GQR1XS
HUTU-80	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXO3clR{UUN3ME2wMlAxQTJ7IN88US=>	MkfjV2FPT0WU
VA-ES-BJ	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEC5PFQh\|ryP	MXrTRW5ITVJ?
GCIY	NV3OVoRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\HWWFZUUN3ME2wMlAyODB5IN88US=>	MnrKV2FPT0WU
ES6	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;UPGlEPTB;MD6wNVA5OyEQvF2=	M4DCUXNCVkeHUh?=
NALM-6	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEGxNFIh\|ryP	NETBfYdUSU6JRWK=
LB996-RCC	M3:1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP6TWM2OD1yLkCxNVM4KM7:TR?=	NIPRNWVUSU6JRWK=
EW-16	NYP1WIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XPcGlEPTB;MD6wNVE6OiEQvF2=	M3zqenNCVkeHUh?=
KALS-1	NFLQeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMEGxPVgh\|ryP	NH;PPYpUSU6JRWK=
OPM-2	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\wTWM2OD1yLkCxNlkh\|ryP	NUjBeG1rW0GQR1XS
KU812	NXjtWmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XqRmlEPTB;MD6wNVI6PiEQvF2=	NEewW5dUSU6JRWK=
A4-Fuk	NEfEVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDQc4dEUUN3ME2wMlAyOzF7IN88US=>	NXTWWmo2W0GQR1XS
KGN	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzzTWM2OD1yLkCxN\|U6KM7:TR?=	M1jJb3NCVkeHUh?=
KS-1	NYPKSFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMEGzPVIh\|ryP	MnH6V2FPT0WU
no-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvk[VBKSzVyPUCuNFE{QTVizszN	NXXkflB3W0GQR1XS
PSN1	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvlOnNKSzVyPUCuNFE1ODlizszN	NYHLZVFxW0GQR1XS
SK-LMS-1	NYXvUZpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nDSGlEPTB;MD6wNVQyOyEQvF2=	M1PzeHNCVkeHUh?=
LS-411N	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{POeWlEPTB;MD6wNVQ{QSEQvF2=	NU\Dfm5SW0GQR1XS
HT-144	NVq5SJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEG0OVEh\|ryP	Ml[wV2FPT0WU
ACN	M{XN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHlTWM2OD1yLkCxOUDPxE1?	MkLCV2FPT0WU
RKO	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\ZNG1KSzVyPUCuNFE2OzNizszN	NHTNSJVUSU6JRWK=
CMK	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTCTWM2OD1yLkCxOVQ{KM7:TR?=	M3nBVXNCVkeHUh?=
GB-1	NF3nPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XQVWlEPTB;MD6wNVU2OyEQvF2=	NXHYeJVbW0GQR1XS
KE-37	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEG1O\|Mh\|ryP	MnvCV2FPT0WU
no-10	M{n6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEG1PFQh\|ryP	MWfTRW5ITVJ?
MOLT-16	NXL6[5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LIWWlEPTB;MD6wNVYzOiEQvF2=	NEi5emhUSU6JRWK=
HEL	NIOwXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFuzWllKSzVyPUCuNFE3PCEQvF2=	NY\6Z5JMW0GQR1XS
NCI-H1355	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLDc\|NKSzVyPUCuNFE3PDZizszN	Mnv2V2FPT0WU
IST-MEL1	NEHmUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH4dXVjUUN3ME2wMlAyPzd2IN88US=>	MWXTRW5ITVJ?
MHH-PREB-1	NEPzVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMEG4NVgh\|ryP	M2ThWnNCVkeHUh?=
ES8	M1\sRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELDbmJKSzVyPUCuNFE5PDRizszN	MU\TRW5ITVJ?
LC-2-ad	NITGXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnhXYZKSzVyPUCuNFIyOzdizszN	M2Hw[XNCVkeHUh?=
LAMA-84	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\BbWlEPTB;MD6wNlE3PyEQvF2=	NXjWRnQ5W0GQR1XS
BV-173	NX;4VJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEKyNFMh\|ryP	NVjD[4tmW0GQR1XS
SW872	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXJSZdKSzVyPUCuNFIzPDdizszN	MWHTRW5ITVJ?
SK-UT-1	NX7mUVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrSfFNjUUN3ME2wMlAzOjZzIN88US=>	NFTvSYhUSU6JRWK=
OS-RC-2	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH1TWM2OD1yLkCyN\|I{KM7:TR?=	NHz3PIVUSU6JRWK=
NCI-H747	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrxTWM2OD1yLkCyN\|Mh\|ryP	NHv0OlhUSU6JRWK=
MZ2-MEL	M2\5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnJNW1KSzVyPUCuNFI{OzdizszN	NViwR4ppW0GQR1XS
TE-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEKzO\|Ih\|ryP	MmT1V2FPT0WU
KURAMOCHI	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7DbGdTUUN3ME2wMlAzPDF2IN88US=>	M2L1R3NCVkeHUh?=
HD-MY-Z	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi1e2NKSzVyPUCuNFI1OjZizszN	NH\W[Y9USU6JRWK=
GI-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEK0Olkh\|ryP	NGTJPXdUSU6JRWK=
LB1047-RCC	NYH2d5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPWbnJjUUN3ME2wMlAzPDh6IN88US=>	Mn:2V2FPT0WU
TE-12	M{GwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13DW2lEPTB;MD6wNlU2KM7:TR?=	M{frSHNCVkeHUh?=
MZ7-mel	NGTpOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzqUYZKSzVyPUCuNFI3ODlizszN	NIfoSYpUSU6JRWK=
MMAC-SF	M{DnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTJTWM2OD1yLkCyOlM{KM7:TR?=	M3XGTHNCVkeHUh?=
A101D	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jYbmlEPTB;MD6wNlY2KM7:TR?=	NWDMc4ZTW0GQR1XS
GR-ST	M2XRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEK2OVUh\|ryP	MV\TRW5ITVJ?
MC116	M3rWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\DcmlEPTB;MD6wNlY5KM7:TR?=	M3\FbXNCVkeHUh?=
Ramos-2G6-4C10	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEK3OUDPxE1?	MnHEV2FPT0WU
ATN-1	NXTrfY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoGxTWM2OD1yLkCyO\|g6KM7:TR?=	MWDTRW5ITVJ?
MFH-ino	NGDUT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2ix[mlEPTB;MD6wNlgyOiEQvF2=	MWjTRW5ITVJ?
DEL	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPOXXJLUUN3ME2wMlAzQDF3IN88US=>	NXW4OXpMW0GQR1XS
OCI-AML2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf1TWM2OD1yLkCyPFcyKM7:TR?=	MWfTRW5ITVJ?
LXF-289	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HNfWlEPTB;MD6wNlg4OiEQvF2=	NYSyb2huW0GQR1XS
IA-LM	M4XqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlz4TWM2OD1yLkCyPVE4KM7:TR?=	MVzTRW5ITVJ?
EoL-1-cell	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\OZoxKSzVyPUCuNFI6QTZizszN	M1\G[nNCVkeHUh?=
OVCAR-4	NH\KV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEOwPVQh\|ryP	MkDSV2FPT0WU
ES1	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEOwPVch\|ryP	MnXXV2FPT0WU
CESS	M2T1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEOwPVkh\|ryP	NF;R[GxUSU6JRWK=
GAK	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjEVXlKSzVyPUCuNFMyQDZizszN	M3fQWXNCVkeHUh?=
NTERA-S-cl-D1	NHzyd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEOyNlYh\|ryP	NV;hPZRmW0GQR1XS
TE-10	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjTTWM2OD1yLkCzN\|EyKM7:TR?=	MVrTRW5ITVJ?
CCRF-CEM	NGHOXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jVTGlEPTB;MD6wN\|M4OSEQvF2=	NEjTfFRUSU6JRWK=
NMC-G1	NYrFdJdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe1c\|JPUUN3ME2wMlA{PDR6IN88US=>	M3zFe3NCVkeHUh?=
HOP-62	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELobGVKSzVyPUCuNFM2PTZizszN	MnzQV2FPT0WU
SH-4	NH31ZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfncXJPUUN3ME2wMlA{PTh{IN88US=>	MmflV2FPT0WU
NCI-H1648	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEO2NlIh\|ryP	NUDMPHBtW0GQR1XS
EB-3	M3yxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn36TWM2OD1yLkCzOlQ{KM7:TR?=	NXHtb3RuW0GQR1XS
BB65-RCC	M1LQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvPTWM2OD1yLkCzOlkyKM7:TR?=	MlO3V2FPT0WU
BE-13	M3X2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEO3OVkh\|ryP	NEXVWmVUSU6JRWK=
CP67-MEL	NYm4RnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEO3OVkh\|ryP	MUPTRW5ITVJ?
SW954	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLxbJV2UUN3ME2wMlA{PzlizszN	NFnkXXdUSU6JRWK=
TE-5	NU\WWVBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfZV2JKSzVyPUCuNFM5PTRizszN	MV3TRW5ITVJ?
HCE-4	NITmNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHUTWM2OD1yLkCzPFU2KM7:TR?=	Mn7pV2FPT0WU
LC-1F	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz1UppKSzVyPUCuNFM6QDlizszN	MU\TRW5ITVJ?
TK10	NWjVcHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnYUmNwUUN3ME2wMlA1ODF7IN88US=>	MkXhV2FPT0WU
SJSA-1	NUC0SVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn64TWM2OD1yLkC0NVg5KM7:TR?=	M2HRVHNCVkeHUh?=
Daudi	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7JTo9KUUN3ME2wMlA1OjJ3IN88US=>	NUjqZWlTW0GQR1XS
SW982	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknOTWM2OD1yLkC0NlQ3KM7:TR?=	MUTTRW5ITVJ?
SF126	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\5[GlEPTB;MD6wOFM3OSEQvF2=	NHHkNoJUSU6JRWK=
TE-15	M{e4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHoUWtKSzVyPUCuNFQ1OzVizszN	NHzVbpZUSU6JRWK=
COLO-684	NIflW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEGxVGdKSzVyPUCuNFQ2PjFizszN	NH7SOoZUSU6JRWK=
8-MG-BA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDMeWdlUUN3ME2wMlA1PjJ7IN88US=>	MYXTRW5ITVJ?
NB13	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O2ZWlEPTB;MD6wOFc4PiEQvF2=	NEDwc2JUSU6JRWK=
HCC1599	NX;kZ256T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7wZ5RqUUN3ME2wMlA1QDd7IN88US=>	M1rzTnNCVkeHUh?=
SK-PN-DW	MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPNTWM2OD1yLkC0PVQ6KM7:TR?=	MYDTRW5ITVJ?
ALL-PO	NXv4WmQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rp[WlEPTB;MD6wOFk2PiEQvF2=	MVLTRW5ITVJ?
NB6	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fsVmlEPTB;MD6wOVI4OSEQvF2=	MlLkV2FPT0WU
IST-SL2	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzITWM2OD1yLkC1N\|YzKM7:TR?=	NXPZfIk6W0GQR1XS
BB30-HNC	MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEW3N{DPxE1?	M{LjNHNCVkeHUh?=
SW962	NGTuR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrld4dVUUN3ME2wMlA2PzZ\|IN88US=>	NYS4e5RyW0GQR1XS
TGBC24TKB	M1jqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXTN\|ZKSzVyPUCuNFU4QTlizszN	MUjTRW5ITVJ?
KINGS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnqTWM2OD1yLkC1PFA{KM7:TR?=	Ml7FV2FPT0WU
HC-1	M1K0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO3RY9CUUN3ME2wMlA2QDJ5IN88US=>	MUXTRW5ITVJ?
RS4-11	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEW5N\|gh\|ryP	NW\KdY85W0GQR1XS
LS-123	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf2VGpKSzVyPUCuNFU6PDJizszN	M4DGbHNCVkeHUh?=
A3-KAW	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Dhc2lEPTB;MD6wOlIzPSEQvF2=	M33zSHNCVkeHUh?=
SNB75	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nxcmlEPTB;MD6wOlM1OSEQvF2=	MnKxV2FPT0WU
SR	M1zW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITqdlNKSzVyPUCuNFY{PzRizszN	NYHSS45XW0GQR1XS
LOUCY	NH;OS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\jUZJKSzVyPUCuNFY{QTRizszN	M4\0dHNCVkeHUh?=
K5	M{[2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\iTWM2OD1yLkC2OFA{KM7:TR?=	Ml\QV2FPT0WU
Becker	M4XGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LBUWlEPTB;MD6wOlQzKM7:TR?=	MV3TRW5ITVJ?
CTV-1	M33kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3rbVVKSzVyPUCuNFY2PDhizszN	NFHGUG1USU6JRWK=
KLE	NImyUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIW0eo1KSzVyPUCuNFY2QDRizszN	M2fCfXNCVkeHUh?=
MZ1-PC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q5RmlEPTB;MD6wOlU6QCEQvF2=	MVjTRW5ITVJ?
MOLT-4	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHkRnZIUUN3ME2wMlA3PjB3IN88US=>	MWXTRW5ITVJ?
MLMA	NFvaelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInnNHNKSzVyPUCuNFY4QCEQvF2=	MWHTRW5ITVJ?
A388	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTtTWM2OD1yLkC2PFk{KM7:TR?=	NWroeZBYW0GQR1XS
MV-4-11	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rafGlEPTB;MD6wOlk6PSEQvF2=	MlztV2FPT0WU
DSH1	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmryTWM2OD1yLkC3NVc{KM7:TR?=	NVvSW2pSW0GQR1XS
MONO-MAC-6	NX3tXHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\DTWM2OD1yLkC3NlEzKM7:TR?=	MknNV2FPT0WU
ARH-77	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13vSWlEPTB;MD6wO\|I4QCEQvF2=	NILXRWxUSU6JRWK=
LB771-HNC	NGe0[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrKTWM2OD1yLkC3OVQ6KM7:TR?=	MY\TRW5ITVJ?
PF-382	M{XOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnyyTWM2OD1yLkC3OVY6KM7:TR?=	NE\JZ5VUSU6JRWK=
KM12	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofRTWM2OD1yLkC3OlQh\|ryP	M4TIR3NCVkeHUh?=
HAL-01	NUL1dmJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEe2OVgh\|ryP	NX\DXHpnW0GQR1XS
RPMI-8402	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMEe3PFkh\|ryP	NVvLdY15W0GQR1XS
OMC-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHUVHFKSzVyPUCuNFc5ODRizszN	NWX5d2lHW0GQR1XS
HT	NYHUUoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMEig{txO	NYTkbm52W0GQR1XS
QIMR-WIL	NY[2VnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3sNI9KSzVyPUCuNFgxPTVizszN	MVPTRW5ITVJ?
KNS-42	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjZb3B{UUN3ME2wMlA5OjB\|IN88US=>	NWnCeldCW0GQR1XS
BC-3	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvPWXdKSzVyPUCuNFgzODRizszN	NHPrUnVUSU6JRWK=
ES4	M1fhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEiyPVYh\|ryP	MkjyV2FPT0WU
NCI-H23	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEi0OEDPxE1?	NFPpXpVUSU6JRWK=
LB2518-MEL	NWnJZW5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfNT2xKSzVyPUCuNFg3QTZizszN	MUHTRW5ITVJ?
LC4-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjrenRKSzVyPUCuNFg4OzhizszN	NEj6dG5USU6JRWK=
SIG-M5	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof4TWM2OD1yLkC4PVA1KM7:TR?=	M{TVXnNCVkeHUh?=
LP-1	NWfMWndyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrHRnRMUUN3ME2wMlA5QTN6IN88US=>	M1m0bXNCVkeHUh?=
TE-8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEmwNVYh\|ryP	NV\adpp1W0GQR1XS
K-562	NFHoVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnpS3VKSzVyPUCuNFkyOiEQvF2=	MUTTRW5ITVJ?
J-RT3-T3-5	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nXVGlEPTB;MD6wPVE2OyEQvF2=	M{XKdXNCVkeHUh?=
DU-4475	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\vTWM2OD1yLkC5NVY2KM7:TR?=	MnKwV2FPT0WU
RXF393	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMEm0OlIh\|ryP	NF;CTGpUSU6JRWK=
NB5	NF3XbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEm2NlUh\|ryP	MmizV2FPT0WU
A704	M3HwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEm3OFEh\|ryP	NXLEUnNEW0GQR1XS
SF268	M4rjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlroTWM2OD1yLkC5PFI2KM7:TR?=	NFHVV5VUSU6JRWK=
UACC-257	NY\qdnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nDWmlEPTB;MD6wPVg{OyEQvF2=	NGLaWWlUSU6JRWK=
L-428	NHrUfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX1OHRKSzVyPUCuNVA{OiEQvF2=	MojnV2FPT0WU
ST486	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMUC2NFYh\|ryP	Mnn3V2FPT0WU
SK-MM-2	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvQTWM2OD1yLkGwO\|A6KM7:TR?=	NVvPc4JZW0GQR1XS
COR-L279	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme4TWM2OD1yLkGwPFMzKM7:TR?=	NEPINlZUSU6JRWK=
JiyoyeP-2003	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUC4OFMh\|ryP	Mn\aV2FPT0WU
GT3TKB	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\Bd4NXUUN3ME2wMlExQTF6IN88US=>	MnzJV2FPT0WU
HCE-T	NFzleoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj3dpZKSzVyPUCuNVA6PCEQvF2=	MkPDV2FPT0WU
SBC-1	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkW0TWM2OD1yLkGxNVE6KM7:TR?=	NIX0e3dUSU6JRWK=
KNS-81-FD	M3fK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWexSYhYUUN3ME2wMlEyOjd\|IN88US=>	MmfEV2FPT0WU
NCI-H2126	M3TudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3uTWM2OD1yLkGxN\|k1KM7:TR?=	NXnaNJREW0GQR1XS
EM-2	M1H2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMUG1Nlkh\|ryP	M1HUWXNCVkeHUh?=
JAR	NXfYRpFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zOV2lEPTB;MD6xNVU6QCEQvF2=	MVHTRW5ITVJ?
NB17	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jHRWlEPTB;MD6xNVY2OiEQvF2=	NEHkU25USU6JRWK=
LB647-SCLC	NFrCPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HLZ2lEPTB;MD6xNVcxPSEQvF2=	M{PBNXNCVkeHUh?=
CAL-148	M1fPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrscFVKSzVyPUCuNVE5KM7:TR?=	MnX1V2FPT0WU
K052	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fqNWlEPTB;MD6xNVg2OSEQvF2=	NELJcJFUSU6JRWK=
KARPAS-299	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMUKyN\|Mh\|ryP	NFfpSVBUSU6JRWK=
KARPAS-422	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMUK0N\|Ih\|ryP	M4rQd3NCVkeHUh?=
LOXIMVI	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYWzUHpYUUN3ME2wMlEzPTF3IN88US=>	MUDTRW5ITVJ?
SCC-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnOwTWM2OD1yLkGyPFUyKM7:TR?=	NGnVOpZUSU6JRWK=
LU-139	NUTEcVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPR[2Z2UUN3ME2wMlEzQTd3IN88US=>	NWDESHJ6W0GQR1XS
COLO-320-HSR	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTrfmNKSzVyPUCuNVMxQDZizszN	M2O2OnNCVkeHUh?=
ONS-76	M3;COWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:wWIs5UUN3ME2wMlE{OTNizszN	Mn6yV2FPT0WU
U-266	NWPz[mlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[0PWlEPTB;MD6xN\|I1PSEQvF2=	NVf2dlB2W0GQR1XS
HH	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzLfGN{UUN3ME2wMlE{PTN3IN88US=>	MYTTRW5ITVJ?
BB49-HNC	M17BWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTwdYlyUUN3ME2wMlE{PTh5IN88US=>	NEjR[nFUSU6JRWK=
NCI-SNU-5	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[2TWM2OD1yLkGzOVk3KM7:TR?=	NIXzeFJUSU6JRWK=
C2BBe1	M{DrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HLTmlEPTB;MD6xN\|c1PiEQvF2=	NH;PenNUSU6JRWK=
ML-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XvVmlEPTB;MD6xN\|k2OyEQvF2=	Ml7GV2FPT0WU
SCH	MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\sTWM2OD1yLkGzPVc1KM7:TR?=	MXTTRW5ITVJ?
NCI-H82	M2G1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMUSxNFQh\|ryP	NEPORVJUSU6JRWK=
MDA-MB-134-VI	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMUSyOVIh\|ryP	NWfOVXd4W0GQR1XS
SK-N-DZ	NIT4bGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfObmhTUUN3ME2wMlE1PzF7IN88US=>	MmPsV2FPT0WU
HL-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMUS5NkDPxE1?	M33O[HNCVkeHUh?=
LB373-MEL-D	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXVR49kUUN3ME2wMlE2PTN7IN88US=>	NHPEVXpUSU6JRWK=
LB831-BLC	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvvZVJ4UUN3ME2wMlE3ODd4IN88US=>	MYXTRW5ITVJ?
SK-NEP-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETrO4dKSzVyPUCuNVYyODFizszN	MWPTRW5ITVJ?
IMR-5	M{f0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PWemlEPTB;MD6xOlQ5OyEQvF2=	MmjhV2FPT0WU
Calu-6	M2\jNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\2O4dKSzVyPUCuNVY2OzdizszN	M{XkXnNCVkeHUh?=
NCI-H1882	NGLCZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfido1jUUN3ME2wMlE3PzJ6IN88US=>	M17Y[XNCVkeHUh?=
NCI-H446	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn20TWM2OD1yLkG2PFkyKM7:TR?=	MXTTRW5ITVJ?
GI-ME-N	Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmKyTWM2OD1yLkG4NFIh\|ryP	MomyV2FPT0WU
MPP-89	NU\URo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTSO4lKSzVyPUCuNVgyOjFizszN	M1\mbHNCVkeHUh?=
CGTH-W-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXnTWM2OD1yLkG4OFM3KM7:TR?=	NFzLTlBUSU6JRWK=
MEG-01	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fiS2lEPTB;MD6xPFYzQCEQvF2=	M4fYb3NCVkeHUh?=
NCI-H748	NXvSVZF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMUi5NVEh\|ryP	MX;TRW5ITVJ?
COLO-829	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fLRmlEPTB;MD6yNFY4OyEQvF2=	MYXTRW5ITVJ?
GOTO	M3jS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LaOWlEPTB;MD6yNFc{KM7:TR?=	M2fwNHNCVkeHUh?=
EW-3	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LUUGlEPTB;MD6yNVcyQCEQvF2=	MoXaV2FPT0WU
KY821	M4PiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHe3VFRKSzVyPUCuNlIxPDVizszN	M4rnWnNCVkeHUh?=
CTB-1	NGD4RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUC0[mVlUUN3ME2wMlIzOjJ6IN88US=>	M{fkenNCVkeHUh?=
TALL-1	M{DqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\mSmlEPTB;MD6yNlkzOSEQvF2=	NWTYelZOW0GQR1XS
NCI-H209	M3LuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfVVVFxUUN3ME2wMlIzQTZ{IN88US=>	Ml7nV2FPT0WU
IST-MES1	NYj2eWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrodVhtUUN3ME2wMlI{PTFizszN	MVTTRW5ITVJ?
DMS-114	M2nRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMkO5PVMh\|ryP	NF7YVXFUSU6JRWK=
SNU-C2B	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMkSzNVYh\|ryP	M2[0enNCVkeHUh?=
DG-75	NXHBNHRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TSV2lEPTB;MD6yOlE6PSEQvF2=	MoL5V2FPT0WU
D-336MG	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy2TIhJUUN3ME2wMlI3PTV5IN88US=>	MXzTRW5ITVJ?
KMOE-2	NGnQRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4q1WGlEPTB;MD6yO\|U{QCEQvF2=	MYrTRW5ITVJ?
NB1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK4TWM2OD1yLkK3PVI3KM7:TR?=	M4\NcXNCVkeHUh?=
RH-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXGTWM2OD1yLkK3PVg6KM7:TR?=	NH25NpdUSU6JRWK=
TE-1	M3HWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMki0O\|kh\|ryP	M2DON3NCVkeHUh?=
RPMI-6666	M1nk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVv1[\|lqUUN3ME2wMlI5QDRizszN	NUn1[GJoW0GQR1XS
TE-9	M2m2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrXTWM2OD1yLkK4PVg2KM7:TR?=	MmDvV2FPT0WU
BT-474	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PI[GlEPTB;MD6yPVM{PCEQvF2=	NHP1dJJUSU6JRWK=
COLO-668	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPUO45MUUN3ME2wMlI6PDJ7IN88US=>	M1PqUXNCVkeHUh?=
NCI-H1581	NYnWTG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\YTWM2OD1yLkK5Olg6KM7:TR?=	NWT0WpJ5W0GQR1XS
MN-60	M4jrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTkTWM2OD1yLkK5PVA2KM7:TR?=	MnzTV2FPT0WU
L-540	M3;wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwM{CwPFEh\|ryP	NGjSRWNUSU6JRWK=
MOLT-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HtSmlEPTB;MD6zNFE5OyEQvF2=	MWnTRW5ITVJ?
NCI-SNU-16	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYi1b2prUUN3ME2wMlMxOjB3IN88US=>	M1G3[XNCVkeHUh?=
NCI-H64	NXzFToh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwM{CzN\|Eh\|ryP	NYX4ZmU{W0GQR1XS
CP66-MEL	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP0TWM2OD1yLkOxOFE2KM7:TR?=	M3j1XHNCVkeHUh?=
NB69	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\x[llKSzVyPUCuN\|IyQDhizszN	MVrTRW5ITVJ?
NCI-H2196	M4qwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHRToxKSzVyPUCuN\|MxOzZizszN	MUPTRW5ITVJ?
MHH-CALL-2	NI\LTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwM{O0Olgh\|ryP	M1LwRXNCVkeHUh?=
HCC2157	NXnMRWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwM{O5OVQh\|ryP	NWPURlA5W0GQR1XS
LS-1034	NWTzbnhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;rTWM2OD1yLkO2N\|g5KM7:TR?=	M4P6b3NCVkeHUh?=
BOKU	M2rRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwM{exPVkh\|ryP	MmGxV2FPT0WU
GDM-1	M2n6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIP6ZWtKSzVyPUCuN\|czOzRizszN	MUfTRW5ITVJ?
TGW	M{S1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fqUGlEPTB;MD6zO\|Q2OyEQvF2=	MXnTRW5ITVJ?
SNU-C1	NFn3Om9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwM{iyNVUh\|ryP	MofuV2FPT0WU
LS-513	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED3NmhKSzVyPUCuN\|kxPzFizszN	NIPmdm1USU6JRWK=
NOMO-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fWN2lEPTB;MD6zPVk4OSEQvF2=	Ml3tV2FPT0WU
MS-1	NYfLbFhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorrTWM2OD1yLkSwNVc4KM7:TR?=	MXPTRW5ITVJ?
EKVX	NVPIbVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnRfG81UUN3ME2wMlQ1PDZzIN88US=>	NX31bplpW0GQR1XS
SK-MEL-2	NF3rb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwNE[0JO69VQ>?	NWrGVlc5W0GQR1XS
HCC1187	M2XIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3KNIhKSzVyPUCuOFY4PjhizszN	NIDHcoJUSU6JRWK=
HCC2218	M1T6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjDboxOUUN3ME2wMlQ4OjJ5IN88US=>	MlraV2FPT0WU
NCI-H187	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXETWM2OD1yLkS3PFQh\|ryP	NWPyXGF[W0GQR1XS
DB	NWnjTGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\LSW1{UUN3ME2wMlUxODV3IN88US=>	M{[xSHNCVkeHUh?=
NCI-H69	M2L5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNUCyOFch\|ryP	MXLTRW5ITVJ?
NCI-H1694	NGTwPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwNUC2PVch\|ryP	MUnTRW5ITVJ?
CA46	NUL5cYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH5TWM2OD1yLkWwPVE4KM7:TR?=	MnnYV2FPT0WU
EHEB	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNUGxPVMh\|ryP	NWTUfZBIW0GQR1XS
NCCIT	NHHGfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPjTWM2OD1yLkW0N\|IyKM7:TR?=	MVTTRW5ITVJ?
NCI-H720	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC3R4J1UUN3ME2wMlU1QTZ{IN88US=>	MX7TRW5ITVJ?
LU-134-A	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\EZ2lEPTB;MD61OVI6PiEQvF2=	MXLTRW5ITVJ?
MC-CAR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfXVpFuUUN3ME2wMlU2PDNzIN88US=>	NIrVN25USU6JRWK=
NEC8	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn5VYFrUUN3ME2wMlU3OTd{IN88US=>	M2nmeHNCVkeHUh?=
NCI-H524	NWX5W5RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf6dYxKSzVyPUCuOVg4PDhizszN	NX;JSY9{W0GQR1XS
NCI-H1963	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fxd2lEPTB;MD62NlU5KM7:TR?=	NWC4SGtkW0GQR1XS
SU-DHL-1	NV3wcG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfv[2lKSzVyPUCuOlQ2OjZizszN	M37YS3NCVkeHUh?=
NCI-H1522	M3nSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnUTWM2OD1yLk[0PFg{KM7:TR?=	MUHTRW5ITVJ?
NCI-H1155	NUPmOXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwNkWzOUDPxE1?	Mk\3V2FPT0WU
D-263MG	M{Lsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\HT2lEPTB;MD62OlExOSEQvF2=	M{DZ[XNCVkeHUh?=
TE-6	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwNkixNFQh\|ryP	MUTTRW5ITVJ?
NCI-H1417	NX3scpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNkm3NVEh\|ryP	MWrTRW5ITVJ?
NCI-H510A	M4\xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnf4TWM2OD1yLke3NlM3KM7:TR?=	NXq1TJI1W0GQR1XS
KARPAS-45	M3O2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3SVHdKSzVyPUCuO\|gzOzVizszN	M2XYPXNCVkeHUh?=
IST-SL1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwOEW4NlUh\|ryP	NVrkbFlqW0GQR1XS
COLO-824	NYTvPGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojETWM2OD1yLki3PFM2KM7:TR?=	MlW4V2FPT0WU
NCI-H526	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\hT3BuUUN3ME2wMlkxQTV6IN88US=>	MnXPV2FPT0WU
NCI-H719	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvnZ4RKSzVyPUCuPVY3PTdizszN	MX\TRW5ITVJ?
SF539	NUnHU5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LSPGlEPTB;MD65PFM6PiEQvF2=	NVnaXVNFW0GQR1XS
NKM-1	NWLQNGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zhZWlEPTB;MD65PFY3OyEQvF2=	NXnERZNyW0GQR1XS
A253	NYjhd2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLOfIJKSzVyPUCuPVg5QDVizszN	Ml7RV2FPT0WU
TE-441-T	NWG0XW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XGcWlEPTB;MT6wOFM2KM7:TR?=	M1rYcXNCVkeHUh?=
COR-L88	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLxTWM2OD1zLkGxN\|U1KM7:TR?=	MVfTRW5ITVJ?
CPC-N	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFu1WJdKSzVyPUGuNVU5QDhizszN	NFqwZnZUSU6JRWK=
NCI-H2107	M2Dwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;4TWM2OD1zLkG3NlYyKM7:TR?=	MXjTRW5ITVJ?
ECC4	M4L6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;LbXFKSzVyPUGuNVg3QTNizszN	M324PHNCVkeHUh?=
NCI-H2141	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSwVmpKSzVyPUGuNVkzQTlizszN	MULTRW5ITVJ?
NCI-H1770	NHTiT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\5SVJIUUN3ME2xMlMzQTJ6IN88US=>	NUP1PINPW0GQR1XS
NCI-SNU-1	NFvCV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDCfIQ2UUN3ME2xMlM{ODRizszN	M17aZXNCVkeHUh?=
LU-165	NGXyRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTFwNEW0Olch\|ryP	NHe1Om1USU6JRWK=
Raji	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTFwNEeyOVkh\|ryP	M{nIdnNCVkeHUh?=
EW-24	NWrjZXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\oOmlEPTB;MT61OFYyQSEQvF2=	M2CyWXNCVkeHUh?=
KP-N-RT-BM-1	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ybGdPUUN3ME2xMlU3PTVzIN88US=>	MXPTRW5ITVJ?
SK-MEL-1	NUXC[I9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTqTWM2OD1zLk[0PFc4KM7:TR?=	NILINnJUSU6JRWK=
SCLC-21H	NXzWeG9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwNk[2OVEh\|ryP	NF\uT\|JUSU6JRWK=
SIMA	NXXub3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnETWM2OD1zLk[4NlM{KM7:TR?=	M4D5[3NCVkeHUh?=
NCI-H1304	M{nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCze5hKSzVyPUGuO\|A4PjVizszN	M1\zfHNCVkeHUh?=
REH	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTFwN{GwO\|gh\|ryP	NGrvWWFUSU6JRWK=
KP-N-YS	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwOUO1OVEh\|ryP	MkX5V2FPT0WU
DMS-153	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwOUe1PUDPxE1?	NHrYfGxUSU6JRWK=
NB10	NEK3SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfsenNKSzVyPUKuNlA5PzhizszN	M1rE[nNCVkeHUh?=
NCI-H345	NHLRbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnTZo5nUUN3ME2yMlYyQTB3IN88US=>	NITneVFUSU6JRWK=
SK-N-FI	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJwN{WzPFEh\|ryP	MknnV2FPT0WU
NCI-H1092	M3PPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVe3Oo1KUUN3ME2yMlk2Ozl2IN88US=>	MYTTRW5ITVJ?
KM-H2	M1fIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K2bmlEPTB;Mz62OVM6PiEQvF2=	MVvTRW5ITVJ?
KG-1	NYrEc5dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUKxR\|IzUUN3ME2zMlcyPjh6IN88US=>	MWDTRW5ITVJ?
D-283MED	NFztPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPBTWM2OD1\|Lke1PFch\|ryP	M2S3bHNCVkeHUh?=
LU-65	NI\ub\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LtS2lEPTB;ND6xNVQ5PSEQvF2=	M{PGNHNCVkeHUh?=
MSTO-211H	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M174O2lEPTB;ND6xPFg6QCEQvF2=	NIe3VotUSU6JRWK=
NCI-H2081	NH;HVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTQTWM2OD12LkK5NVc1KM7:TR?=	Moi1V2FPT0WU
D-247MG	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTRwNEOxPVEh\|ryP	NIHtOZBUSU6JRWK=
P31-FUJ	NYSxXYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3mwd2lEPTB;ND60OVAyQSEQvF2=	NWDmU3hVW0GQR1XS
DMS-79	NFmxT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLITWM2OD12LkmzNVg{KM7:TR?=	MW\TRW5ITVJ?
KASUMI-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwOUe1NFkh\|ryP	MWjTRW5ITVJ?
JVM-3	M{DIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4POOWlEPTB;NT6yOVAyPCEQvF2=	MW\TRW5ITVJ?
LAN-6	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXETYI2UUN3ME21MlUyPzN4IN88US=>	NFjjc5BUSU6JRWK=
DJM-1	NIjP[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i2TmlEPTB;NT61OlAzQSEQvF2=	MXzTRW5ITVJ?
JVM-2	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojRTWM2OD13Lk[3NFkzKM7:TR?=	NISxNYFUSU6JRWK=
U-87-MG	NI\6OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vWOGlEPTB;NT64PVk3PCEQvF2=	Mn\NV2FPT0WU
SHP-77	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7lTWM2OD13Lkm0PVI5KM7:TR?=	Ml\1V2FPT0WU
RPMI-8866	M{\HWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2WwXmlEPTB;Nj6yO\|AyOyEQvF2=	NVzL[4ZDW0GQR1XS
ES7	NIGwWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTZwM{m5NlQh\|ryP	NXjKZ2Q6W0GQR1XS
WSU-NHL	NIjTNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzzTWM2OD14LkWxOlA6KM7:TR?=	M2nKcnNCVkeHUh?=
CAS-1	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f4R2lEPTB;Nz6wPVc1QSEQvF2=	NX[zZ3FtW0GQR1XS
MHH-NB-11	Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnwTFZKSzVyPUiuNlMyPTJizszN	MUTTRW5ITVJ?
ES5	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LqbGlEPTB;OT61NlI5PiEQvF2=	NI\rXGhUSU6JRWK=
HDLM-2	M17Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfkTWM2OD17Lkm1PVAzKM7:TR?=	MmfTV2FPT0WU
NCI-H2171	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTFyLkW5Nlch\|ryP	MWjTRW5ITVJ?
LNCaP-Clone-FGC	M1zmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moe4TWM2OD1zMT6zO\|E5KM7:TR?=	MkHFV2FPT0WU
NCI-H1395	Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF{LkK2PVkh\|ryP	MYDTRW5ITVJ?
NCI-H1436	NWTKbFJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF\|LkOxPVUh\|ryP	MnTNV2FPT0WU
RCC10RGB	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGOwc3RKSzVyPUGzMlMzOjFizszN	NWrVWY0yW0GQR1XS
SW684	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUn2bGxmUUN3ME2xN{46Pzl5IN88US=>	NX7HVJd[W0GQR1XS
NCI-H1650	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnnVI5IUUN3ME2xOU4xPDR5IN88US=>	M{C1cHNCVkeHUh?=
EW-13	NWrOXFdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXFR4dlUUN3ME2xOU4zODJzIN88US=>	M3PkTXNCVkeHUh?=
EC-GI-10	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHiXmRKSzVyPUG1Mlg3PDRizszN	M3r1c3NCVkeHUh?=
CHP-126	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\mZ2lEPTB;MUeuNVkyQCEQvF2=	MoPBV2FPT0WU
NCI-H226	NVLOd\|BKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnVTJFKSzVyPUG4MlA1ODNizszN	MmrKV2FPT0WU
NCI-H1838	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFizcnRKSzVyPUKwMlE5PDhizszN	NGeyXmlUSU6JRWK=
EW-11	NH3q[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r2PGlEPTB;MkSuNlcyQCEQvF2=	M4PLNXNCVkeHUh?=
EB2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rOS2lEPTB;M{GuOVMyQCEQvF2=	M1zsO3NCVkeHUh?=
D-502MG	M1LYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkOxTWM2OD12Mz65NlI6KM7:TR?=	NEKybHlUSU6JRWK=
U-698-M	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTR6Lki2O\|Eh\|ryP	NF;WPY5USU6JRWK=
ES3	M4LoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXQTWM2OD12OT6zPFk{KM7:TR?=	NEj0V2dUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1